Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Blood (2023) 142 (Supplement 1): 823.

https://doi.org/10.1182/blood-2023-177798

Published: 2023

Journal Articles

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Leonard A. Mattano, MD, Meenakshi Devidas, PhD, Alison M. Friedmann, MD MSC, Elizabeth A. Raetz, MD, Mignon Loh, MD, Patrick Buckley, MD PhD, Michael J. Borowitz, MD PhD, Andrew J. Carroll, PhD, Julie Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan-Lottick, MD MSPH, Yousif Matloub, MD, David T Marshall, MD, Linda C. Stork, MD, Brent L. Wood, MD PhD, Naomi J. Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Kelly Maloney, MD

Blood (2014) 124 (21): 793.

https://doi.org/10.1182/blood.V124.21.793.793

Published: 2014

Journal Articles

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Kelly W. Maloney, MD, Meenakshi Devidas, PhD, Leonard A. Mattano, Jr., MD, Alison M. Friedmann, MD, MSC, Patrick Buckley, MD, PhD, Michael J. Borowitz, MD, PhD, Andrew J. Carroll, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Nina Kadan -lottick, Mignon L. Loh, MD, Yousif Matloub, MD, David T. Marshall, MD, Linda C. Stork, MD, Elizabeth A. Raetz, MD, Brent L. Wood, MD, PhD, Naomi J. Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2013) 122 (21): 837.

https://doi.org/10.1182/blood.V122.21.837.837

Published: 2013

Journal Articles

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Yousif Matloub, Bruce C. Bostrom, Stephen P. Hunger, Linda C. Stork, Anne Angiolillo, Harland Sather, Mei La, Julie M. Gastier-Foster, Nyla A. Heerema, Scott Sailer, Patrick J. Buckley, Blythe Thomson, Catherine Cole, James B. Nachman, Gregory Reaman, Naomi Winick, William L. Carroll, Meenakshi Devidas, Paul S. Gaynon

Blood (2011) 118 (2): 243–251.

https://doi.org/10.1182/blood-2010-12-322909

Published: 2011

Journal Articles

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Linda C. Stork, Yousif Matloub, Emmett Broxson, Mei La, Rochelle Yanofsky, Harland Sather, Ray Hutchinson, Nyla A. Heerema, April D. Sorrell, Margaret Masterson, Archie Bleyer, Paul S. Gaynon

Blood (2010) 115 (14): 2740–2748.

https://doi.org/10.1182/blood-2009-07-230656

Published: 2010

Journal Articles

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

Bill H Chang, MD, PhD, Stephanie G Willis, Linda C. Stork, MD, Stephen P Hunger, MD, William L. Carroll, MD, Bruce Camitta, MD, Naomi J. Winick, MD, Brian J. Druker, MD, Kirk R. Schultz, MD

Blood (2009) 114 (22): 2634.

https://doi.org/10.1182/blood.V114.22.2634.2634

Published: 2009

Journal Articles

Failure of Asparagine (ASN) Depletion, Not Inadequate Asparaginase (ASNase) Activity, Predicts Relapse in Standard Risk (SR) Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Vassilios I. Avramis, PhD, John S. Holcenberg, MD, Alice G. Ettinger, RN, Linda C. Stork, MD, Mei La, MS, Paul S. Gaynon, MD

Blood (2007) 110 (11): 588.

https://doi.org/10.1182/blood.V110.11.588.588

Published: 2007

Journal Articles

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Faith C. Galderisi, DO, Linda C. Stork, MD, Ju Li, MD, Motomi Mori, PhD, Solange Mongoue-Tchokote, James Huang, MD

Blood (2007) 110 (11): 4232.

https://doi.org/10.1182/blood.V110.11.4232.4232

Published: 2007

Journal Articles

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Janet K. Dale, RN, Susan Price, RN, Jean Tretler, RN, Patricia Aldridge, RN, Stephanie Montague, RN MSN, Joie Davis, APRN, Fred Gill, MD, Kip R. Hartman, MD, Linda C. Stork, MD, David J. Gnarra, MD, Lakshmanan Krishnamurti, MD, Jennifer Puck, MD, Thomas Fleisher, MD, V. Koneti Rao, MD

Blood (2007) 110 (11): 1319.

https://doi.org/10.1182/blood.V110.11.1319.1319

Published: 2007

Journal Articles

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Yousif Matloub, Susan Lindemulder, Paul S. Gaynon, Harland Sather, Mei La, Emmett Broxson, Rochelle Yanofsky, Raymond Hutchinson, Nyla A. Heerema, James Nachman, Marilyn Blake, Linda M. Wells, April D. Sorrell, Margaret Masterson, John F. Kelleher, Linda C. Stork

Blood (2006) 108 (4): 1165–1173.

https://doi.org/10.1182/blood-2005-12-011809

Published: 2006

Journal Articles

Early Marrow Response in CCG-1952: The Prognostic Impact of Poor Day 14 Marrow Response Is Powerful and Only Partially Reversible with Intensified Therapy.

Robert Cho, MD, Linda C. Stork, MD, Paul S. Gaynon, MD, Harland N. Sather, PhD, Mei K. La, MS, Raymond J. Hutchinson, MD

Blood (2005) 106 (11): 867.

https://doi.org/10.1182/blood.V106.11.867.867

Published: 2005

Journal Articles

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Suman Malempati, MD, Paul S. Gaynon, MD, Harland Sather, PhD, Mei K. La, MS, Linda C. Stork, MD

Blood (2004) 104 (11): 520.

https://doi.org/10.1182/blood.V104.11.520.520

Published: 2004

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

Journal Articles

Pharmacodynamic (PD) Analyses of Asparagine (Asn) Deamination and Asn Input (Imax) in Serum of Pediatric Patients with Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Receiving Native or Pegylated E. Coli Asparaginases (ASNase) (CCG-1962).

Vassilios I. Avramis, Ph.D., Eduard H. Panosyan, M.D., Cecilia H. Fu, M.D., Linda C. Stork, M.D., Paul S. Gaynon, M.D.

Blood (2004) 104 (11): 2082.

https://doi.org/10.1182/blood.V104.11.2082.2082

Published: 2004

NARROW

Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331

Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children’s Oncology Group (COG) AALL0331

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

Failure of Asparagine (ASN) Depletion, Not Inadequate Asparaginase (ASNase) Activity, Predicts Relapse in Standard Risk (SR) Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Early Marrow Response in CCG-1952: The Prognostic Impact of Poor Day 14 Marrow Response Is Powerful and Only Partially Reversible with Intensified Therapy.

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Pharmacodynamic (PD) Analyses of Asparagine (Asn) Deamination and Asn Input (Imax) in Serum of Pediatric Patients with Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Receiving Native or Pegylated E. Coli Asparaginases (ASNase) (CCG-1962).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only